LegitScript to certify clinics that sell six HHS peptides
Also in this issue: Ad platforms still set their own rules
Forwarded this? Get it weekday mornings.
Take. Certification is the easy gate. Meta and Google are the hard one, and neither has said a word. Expect the first wave of peptide marketing to run on email, referrals and organic search while the ad platforms decide. Clinics that build those lists now will spend less to win each patient later.
LegitScript changed its certification review on Monday. Offering BPC-157, TB-500, Epitalon, Semax, KPV or MOTS-c in the forms and routes the HHS policy covers no longer blocks certification by itself. Ad platforms and payment processors use LegitScript to vet pharmacy and telehealth advertisers.
The limits are tight. Only qualifying 503A pharmacies and physician compounders count. 503B outsourcing facilities are left out. Products must be single-ingredient, so a BPC-157 and TB-500 blend still fails. Syringes must be FDA 510(k)-cleared, which rules out pens.
LegitScript also wrote that certification "does not guarantee access" to advertising platforms or payment providers. That cuts against posts on X claiming LegitScript had opened Meta ads for these peptides. Pink Sheet reports that the HHS policy itself says nothing on advertising claims.
HHS published the policy in the Federal Register on Oct. 30. It says HHS won't pursue 503A compounders for these peptides under stated conditions. It approves no drug.
Tools and Tech
Cerbo and OptiMantra now share one parent, Providi
Two EHRs that many cash-pay longevity, medspa and functional clinics run on now sit under one company. The Mainsail-backed parent launched the Providi brand last week, per its PR Newswire release. Both products keep their names. Together they serve nearly 7,000 cash-pay clinics. Cerbo's AI scribe is live. OptiMantra's is listed as "coming soon."
We read this as a price signal. One owner across 7,000 clinics has room to bundle the AI scribe and charge for it. OptiMantra clinics should ask what the scribe will cost before renewal.
The Signal
Coverage
Fewer employers cover GLP-1s for weight loss in 2027
WTW surveyed 471 U.S. employers and found 53% cover GLP-1s for weight loss, down from 57%. Of those still covering, 30% are thinking about dropping it. Federal workers get a tighter plan too. OPM will require documented behavioral therapy before and during anti-obesity drug treatment in 2027. The Mail Handlers Benefit Plan's 2027 brochure puts those drugs on a tier paying 50% of plan allowance with no per-prescription cap. Federal open season runs Nov. 9 to Dec. 14. Patients who lose coverage in January will compare clinics against manufacturer self-pay. CNBC lists the Wegovy shot from $199 a month and Zepbound from $299.
Marketing
Google charges health clinics for some missed LSA calls
Google's Local Services Ads help page says a missed call during business hours becomes a paid lead once the caller stays on more than 20 seconds. U.S. health care gets no lead credits. Clinics listing hours past front-desk staffing pay for ring-outs.
Everyone
Bios Wellness buys a Houston hormone and peptide practice
Bios Wellness Clinics bought Dr. Shel Wellness & Aesthetics, the 20-year Houston practice of Shelena Lalji, MD. The menu runs from BHRT and peptides to IV, injectables and lasers. It is Bios' third U.S. deal in three months and its first in Texas, per a PRWeb release from the seller's advisor, Practice Transitions Group. No price was disclosed. A buyer paying for hormone-heavy books gives BHRT owners an exit that used to belong to injectables clinics.
Telehealth
Telehealth GLP-1 promos undercut posted prices on Reddit
Patients on Reddit posted a $99 Pomegranate Halloween offer and a CosmeticRx tirzepatide cut to $119. Neither shows on the sellers' pages. Pomegranate lists compounded tirzepatide from $159 a month. CosmeticRx lists it at $299. The promos are patient reports we couldn't confirm. Posted prices may overstate what a competitor charges a lapsed patient.
Everyone
GrowthCurve takes control of TailorMed
GrowthCurve Capital is buying a majority of TailorMed, which matches patients to drug-assistance programs at 950+ hospitals. Dealroom cites a reported $250M valuation.
Who's Building
LaserAway filed a $224,224 fit-out for a SoHo clinic at 453 West Broadway with NYC Buildings. Manhattan independents get another national laser chain nearby.
LaserAway has 10 Texas build-out registrations in 12 months on TDLR's project registry. The latest is Cedar Park, at $450,000 for 2,000 square feet, with work scheduled to start this week. Houston's Champion Forest and Irving run $342,031 and $450,000. That is a ready benchmark for what a chain spends on a small aesthetics clinic.
Hims & Hers has a Mesa permit for a demising wall in a second warehouse at 8138 E Pecos Rd, beside its 8142 E Pecos plant. The permit shows build-out work only, not lease terms.
QuVa Pharma, a 503B outsourcing facility, registered a $1 million lab expansion at 1005 Industrial Blvd in Sugar Land, Texas, per TDLR. More QC capacity bears on supply for clinics that buy office-use 503B product.
Wire
- The Deal Wire says Santander and J.P. Morgan underwrote an $800M bridge loan for Galderma's purchase of ZO Skin Health from Blackstone.
- MarketBeat has Hims & Hers reporting after the close Monday, Nov. 9, with a 5 p.m. ET call.
- DEA's telemedicine flexibilities end Dec. 31 unless DEA extends or replaces them.
Optimized Daily Report is business news for clinic operators. Not medical, legal, or investment advice. Company claims are the company's.